stage renal disease (ESRD), chronic kidney disease (CKD) has also been reported to be associated with an elevated risk of cardiovascular disease (CVD) [1] [2] [3] . A recent study reported an increased risk of coronary heart disease (CHD) in patients with CKD 4) . In Japan, patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m 2 have been estimated to account for about 10% of the entire population 5, 6) . Early diagnosis and prompt treatment of
Introduction
In addition to the risk of progression to end-CKD are important for the prevention of CVD and reduction of mortality and morbidity 1) . In a sub-analysis of the Treating to New Targets (TNT) study, treatment with 10 mg and 80 mg atorvastatin was found to increase the eGFR by 3.5 mL/ min/1.73 m 2 and 5.2 mL/min/1.73 m 2 , respectively 7) . In contrast, in the Prevention of Renal and Vascular ENd-stage Disease Intervention trial (PREVEND-IT), treatment with 40 mg pravastatin did not result in any change of the eGFR 8) . Thus, the beneficial effect of statins on the eGFR remained controversial.
The LIVALO Effectiveness and Safety (LIVES) Study was a large-scale, long-term, prospective postmarketing surveillance study of pitavastatin 9) . Since it included more than 20,000 hypercholesterolemic patients and was a prospective surveillance study, the database of the LIVES Study is considered to be useful for evaluation of the efficacy and safety of pitavastatin in routine clinical practice. Sub-analysis of the LIVES Study showed that pitavastatin significantly increased serum HDL-C 10) . In the present study, using the LIVES Study database, we analyzed the effect of pitavastatin on the eGFR in patients with a baseline eGFR of 60 mL/min/1.73 m 2 .
Subjects and Methods

Survey Participants
The design and results of the LIVES Study have been reported previously 9) . Patients with hypercholesterolemia, including familial hypercholesterolemia, were enrolled in this study using a central registration system, with each patient enrolled within 14 days of the start of treatment with pitavastatin. Patients were observed for 2 years after the start of treatment. Of the 20,279 patients recruited, 19,925 were included in the safety analysis and 18,031 in the efficacy analysis of pitavastatin.
The major objective of the LIVES Study was to investigate the occurrence of any unknown adverse reactions and to evaluate the incidence and pattern of adverse reactions of pitavastatin. In the 19,925 patients included in the safety analysis, the eGFR was calculated in patients for whom all data were available after 104 weeks' treatment with pitavastatin. Seven patients with serum creatinine levels above the normal range were excluded from the analysis as outliers.
eGFR Analysis
eGFR was assessed using the new Japanese revised equation 11) , as follows: eGFR (mL/min/ According to the baseline eGFR, the patients were classified into CKD stages as defined in the K/DOQI guideline 12) , as follows: stage 1 ( ≥ 90), stage 2 ( ≥ 60 − 90), stage 3 ( ≥ 30 − 60), stage 4 ( ≥ 15 − 30), and stage 5 ( 15) . Patients with baseline eGFR values 60 mL/min/1.73 m 2 were enrolled for sub-analysis. Furthermore, the time-course of changes in the eGFR was evaluated at 0, 12, 28, 52 and 104 weeks in patients with a baseline eGFR of 60 mL/ min/1.73 m 2 for whom all data were available after 104 weeks of pitavastatin treatment. The time-course of changes in the eGFR was analyzed using repeated measures ANOVA.
Lipid Profile Analysis
The percent changes of serum TC, LDL-C, TG (in the entire study population and in the high TG group ( ≥ 150 mg/dL) at baseline), HDL-C (in the entire study population and in the low HDL-C group ( 40 mg/dL) at baseline), non-HDL-C and LDL-C/ HDL-C were calculated in patients with a baseline eGFR of 60 mL/min/1.73 m 2 . The serum concentration of LDL-C was estimated using the Friedewald formula (LDL-C TC-HDL-C-TG 0.2) 13) in patients with serum TG concentrations of less than 400 mg/dL. Correlations between the degree of change in the eGFR and that of the changes in the serum TC, LDL-C, TG, HDL-C, non-HDL-C and LDL-C/ HDL-C were analyzed in patients with a baseline eGFR of less than 60 mL/min/1.73 m 2 .
Analysis of the Clinical Factors Affecting Changes in the eGFR during Pitavastatin Treatment
The clinical factors affecting the changes in the eGFR during pitavastatin treatment were analyzed in patients with a baseline eGFR of 60 mL/min/1.73 m 2 . The patient baseline characteristics (gender, age, BMI and smoking history), presence/absence of underlying diseases (hypertension, diabetes and heart disease), presence/absence of proteinuria by the urinary dipstick test ( -or more), history/no previous history of lipid-lowering medication, the initial dose of pitavastatin, and the amount change of serum lipids (LDL-C, TG, and HDL-C) were entered into a multivariate regression model for this analysis.
Statistical Analysis
All data were expressed as the mean standard deviation. Statistical analysis was performed with a one-sample t test or paired t test, or a two-sample t test, as appropriate. One-way analysis of variance (ANOVA) and linear regression analysis were performed to analyze the time-course of changes in the eGFR. In factorial analysis, changes in the eGFR were analyzed after adjustment for the baseline eGFR by ANOVA (F-test). Furthermore, multivariate analysis was applied by the stepwise method to identify factors that affected changes in the eGFR during treatment. JMP ver. 5.1.1 was used for all statistical analyses. The significance level was set at 0.05 (two-sided).
Results
Effects on Renal Function
Of the 19,925 patients, 3,119 for whom the relevant data were available were included to evaluate changes in the eGFR after 104 weeks pitavastatin treatment. The patients were classified into CKD stages according to the baseline eGFR. The number of patients in each stage is shown in Table 1 . Of the patients included in this analysis, the baseline eGFR was ≥ 60 mL/min/1.73 m 2 in 2,161 patients and 60 mL/min/1.73 m 2 in 958 patients. The demographic characteristics of these patients are shown in Table 2 . The two groups were similar except for the mean age, hyperlipidemia phenotype, and prevalence of hypertension and renal disease. Patients with an eGFR of 60 mL/min/1.73 m 2 were included for the following analysis as cases of impaired renal function.
The changes in the eGFR at 104 weeks are shown in Fig. 1 . A significant increase in the eGFR from 47. 8 11 , n 488, p 0.001) (data not shown). Furthermore, in regard to the time-course of changes in the eGFR during pitavastatin treatment, the increase in the eGFR was 2.4 mL/min/1.73 m 2 at 12 weeks, and 5.6 mL/min/1.73 m 2 at 104 weeks (p 0.001; Repeated measures ANOVA) (Fig. 2) .
Effects of Pitavastatin Treatment on Plasma Lipid Levels
The percent changes in serum lipid levels at 104 weeks are listed in Table 3 . A significant reduction of the serum TC ( 22.5%) and LDL-C ( 31.3%) was observed at 104 weeks. Serum non-HDL-C and LDL-C/HDL-C were also reduced significantly (p 0.0001) There were no significant correlations between the changes of the eGFR and those of serum TC, LDL-C, TG, non-HDL-C or LDL-C/HDL-C ( Table 4) . A weak correlation was observed between the change in the eGFR and that of serum HDL-C following pitavastatin treatment (r 0.092; p 0.013).
Analysis of the Clinical Factors Affecting Changes in the eGFR During Pitavastatin Treatment
The clinical factors affecting changes in the eGFR during pitavastatin treatment are shown in Table 5 . According to the results of ANOVA (F-test), gender, age, presence/absence of hypertension, diabetes, heart disease, proteinuria, and history/no previous history of lipid-lowering medication were identified as significant factors affecting changes in the eGFR during pitavastatin treatment.
Multivariate analysis by the stepwise method was used to identify the factors influencing changes in the eGFR during pitavastatin treatment. The results identified the presence/absence of proteinuria and the amount change of HDL-C as significant factors influencing changes in the eGFR during pitavastatin treatment ( Table 6 ). Changes in the eGFR in the presence/ absence of hypertension, diabetes, and proteinuria are shown in Fig. 3 . The increase in the eGFR in patients with diabetes/hypertension was less than that in patients without diabetes/hypertension. Similar results were obtained in patients with/without proteinuria.
Safety
Of the 19,925 patients included in the safety evaluation in the LIVES study, 2,069 patients (10.4%) developed adverse drug reactions 9) . Of the 3,119 patients included in the present analysis, 173 (5.5%) developed adverse drug reactions. Myopathy-associated adverse reactions were seen in 74 patients (2.4%), and hepatic adverse reactions in 68 patients (2.2%). 
Discussion
In this study, a significant increase of the eGFR was seen after pitavastatin treatment for 104 weeks in hypercholesterolemic patients with a baseline eGFR of 60 mL/min/1.73 m 2 . In view of the decrease of the eGFR by 0.36 mL/min/1.73 m 2 per year in healthy Japanese subjects 14) , the increase in eGFR by 5.4 mL/ min/1.73 m 2 induced by pitavastatin treatment after 104 weeks in patients with a baseline eGFR of 60 mL/min/1.73 m 2 is noteworthy. The increase in the eGFR observed after pitavastatin treatment in the present study is similar to that reported for other statins, i.e. 3.5 and 5.2 mL/min/1.73 m 2 for 10 mg and 80 mg atorvastatin 7) and 4.8 mL/min/1.73 m 2 for rosvastatin 15) . Thus, it was confirmed in this study that the increase in eGFR is a class effects of statins. Athyros et al. reported that the increase in the eGFR induced by statins was also related to a reduction in the hazard ratio for CHD 16) . In sub-analysis of the TNT trial 4, 7) , 80 mg atorvastatin produced greater elevation of the eGFR and reduction of the CVD risk than 10 mg atorvastatin in patients with CKD.
The possible mechanisms underlying the increase in the eGFR induced by statins have been reported in several papers and include improvement of the endothelial function 17) . Statins have also been suggested to increase renal blood flow and suppress monocyte recruitment, mesangial cell proliferation, and inflammation 18) . Nakamura et al. reported that pitavastatin reduced urinary albumin and liver-type fatty acidbinding protein (L-FABP) in patients with early diabetic nephropathy, which might be attributable to the antioxidant effects of pitavastatin 19) . In spontaneously hypercholesterolaemic Imai rats, pitavastatin showed a renal protective effect via reduction of the urinary protein and antioxidant actions, independent of the lipidlowering effects 20) . Thus, we assume that the increased eGFR observed in the present study could be attributed to the pleiotropic effects of pitavastatin. Meanwhile, changes in the eGFR were significantly related with those of serum HDL-C in this analysis, although the correlation coefficient was small. Also, the amount change of HDL-C was identified as a significant factor influencing changes in the eGFR during pitavastatin treatment; therefore, the increase of HDL-C might be attributed to the increase of the eGFR. In fact, the results of sub-analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study suggested a relation between increased serum HDL-C and increased eGFR following atorvastatin treatment 21) . The antioxidant effects of HDL-C were considered to possibly underlie this correlation 22) ; however, further analysis is needed to clarify the mechanism underlying the increase of the eGFR induced by pitavastatin.
At the baseline, the percentage of patients with an eGFR 60 mL/min/1.73 m 2 was 30.7% in this sub-analysis, higher than that estimated in the Japanese general population, which is about 10% 5, 6) . Therefore, it may be assumed that CKD is more prevalent in hypercholesterolemic patients than in the general population. Indeed, in a sub-analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study 23) conducted in mild hypercholesterolemic patients, the percentage of patients with an eGFR between 30 and 60 mL/min per 1.73 m 2 was higher than in the general population.
In factorial analysis of the current sub-analysis, proteinuria was identified as a significant factor attenuating the elevation of the eGFR observed during pitavastatin treatment. Proteinuria is known as a major factor related to the decline of eGFR and the progression of renal disease 14, 24) ; therefore, it is understandable why patients with proteinuria showed a less pronounced effect of pitavastatin in increasing the eGFR in this study. Diabetes was identified as a factor attenuating the elevation of eGFR during pitavastatin treatment with borderline significance (p 0.0512). Diabetes is well known to be associated with the progressive impairment of renal function. The rate of renal function deterioration in CKD patients is higher in those with than without diabetes 25) . The increase of the eGFR in patients taking an ACE inhibitor or ARB was lower than in patients not under treatment with these classes of drugs. The baseline eGFR in patients with an ACE inhibitor or ARB was significantly lower than in patients without an ACE inhibitor or ARB; therefore, patients taking an ACE inhibitor or ARB might show less increase of eGFR because of severe renal dysfunction; however, it is also possible that ACE-I/ARB treatment affects the potency of pitavastatin for the eGFR directly.
In this study, we analyzed the effects of pitavastatin on the eGFR under actual use conditions using the database of the LIVES Study. Since the LIVES Study is post-marketing surveillance study, there is no control group; thus, a further randomized controlled trial is needed to confirm the effects of pitavastatin on the eGFR.
In conclusion, pitavastain showed a significant increase of the eGFR after treatment for 104 weeks, suggesting that pitavastatin might maintain the glomerular filtration rate and also contribute to reduce the risk of CVD in patients with CKD. Further prospective long-term clinical trials are needed for more precise evaluation of the effects of pitavastatin on renal function.
